Shares of Immatics (NASDAQ: IMTX) soared in morning trading at the time of publishing on Tuesday after the clinical-stage biopharmaceutical company gave an interim clinical data update for 11 heavily pre-treated, last-line patients with recurrent and/or refractory solid cancers treated with ACTengine IMA203 TCR-T monotherapy in the ongoing Phase 1b dose expansion Cohort A.
This data indicated that overall, “IMA203 showed a high rate of deep and durable objective responses, with a confirmed objective response rate of 67% (6/9), across multiple tumor types, including two confirmed partial responses (cPR) ongoing at more than 9 months after treatment and three additional partial responses ongoing at data cut-off.”
Analysts are bullish about IMTX stock with a Strong Buy consensus rating based on unanimous three Buys.
